Carprofen

CHEMBL1316 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
273.7 g/mol
LogP
4.0
Phase
4

A nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing the production of prostaglandins responsible for pain and inflammation. While it was once used in humans, it is now primarily employed in veterinary medicine for pain relief in dogs. Gastrointestinal and renal adverse effects are associated with its use.

Molekularmasse

273,7100 g/mol

LogP

4,00

TPSA

53,10 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C(=O)O)c1ccc2c(c1)[nH]c1ccc(Cl)cc12

InChI

InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)

Molecular Formula

C15H12ClNO2

HBD / HBA

2 / 2

Rotierbare Bindungen

2

Schwere Atome

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing the production of prostaglandins responsible for pain and inflammation. While it was once used in humans, it is now primarily employed in veterinary medicine for pain relief in dogs. Gastrointestinal and renal adverse effects are associated with its use.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Carprofen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1316. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2581. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.